214 related articles for article (PubMed ID: 19944696)
1. Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner.
Mee CJ; Farquhar MJ; Harris HJ; Hu K; Ramma W; Ahmed A; Maurel P; Bicknell R; Balfe P; McKeating JA
Gastroenterology; 2010 Mar; 138(3):1134-42. PubMed ID: 19944696
[TBL] [Abstract][Full Text] [Related]
2. Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner.
Fletcher NF; Sutaria R; Jo J; Barnes A; Blahova M; Meredith LW; Cosset FL; Curbishley SM; Adams DH; Bertoletti A; McKeating JA
Hepatology; 2014 Apr; 59(4):1320-30. PubMed ID: 24259385
[TBL] [Abstract][Full Text] [Related]
3. A dual role for hypoxia inducible factor-1α in the hepatitis C virus lifecycle and hepatoma migration.
Wilson GK; Brimacombe CL; Rowe IA; Reynolds GM; Fletcher NF; Stamataki Z; Bhogal RH; Simões ML; Ashcroft M; Afford SC; Mitry RR; Dhawan A; Mee CJ; Hübscher SG; Balfe P; McKeating JA
J Hepatol; 2012 Apr; 56(4):803-9. PubMed ID: 22178269
[TBL] [Abstract][Full Text] [Related]
4. Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells.
Mee CJ; Harris HJ; Farquhar MJ; Wilson G; Reynolds G; Davis C; van IJzendoorn SC; Balfe P; McKeating JA
J Virol; 2009 Jun; 83(12):6211-21. PubMed ID: 19357163
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus envelope components alter localization of hepatocyte tight junction-associated proteins and promote occludin retention in the endoplasmic reticulum.
Benedicto I; Molina-Jiménez F; Barreiro O; Maldonado-Rodríguez A; Prieto J; Moreno-Otero R; Aldabe R; López-Cabrera M; Majano PL
Hepatology; 2008 Oct; 48(4):1044-53. PubMed ID: 18802961
[TBL] [Abstract][Full Text] [Related]
6. Infection with hepatitis C virus depends on TACSTD2, a regulator of claudin-1 and occludin highly downregulated in hepatocellular carcinoma.
Sekhar V; Pollicino T; Diaz G; Engle RE; Alayli F; Melis M; Kabat J; Tice A; Pomerenke A; Altan-Bonnet N; Zamboni F; Lusso P; Emerson SU; Farci P
PLoS Pathog; 2018 Mar; 14(3):e1006916. PubMed ID: 29538454
[TBL] [Abstract][Full Text] [Related]
7. Single Particle Imaging of Polarized Hepatoma Organoids upon Hepatitis C Virus Infection Reveals an Ordered and Sequential Entry Process.
Baktash Y; Madhav A; Coller KE; Randall G
Cell Host Microbe; 2018 Mar; 23(3):382-394.e5. PubMed ID: 29544098
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system.
Zhu H; Dong H; Eksioglu E; Hemming A; Cao M; Crawford JM; Nelson DR; Liu C
Gastroenterology; 2007 Nov; 133(5):1649-59. PubMed ID: 17983809
[TBL] [Abstract][Full Text] [Related]
9. Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.
Peng S; Wang Y; Peng H; Chen D; Shen S; Peng B; Chen M; Lencioni R; Kuang M
Hepatology; 2014 Oct; 60(4):1264-77. PubMed ID: 24849467
[TBL] [Abstract][Full Text] [Related]
10. The SR-BI partner PDZK1 facilitates hepatitis C virus entry.
Eyre NS; Drummer HE; Beard MR
PLoS Pathog; 2010 Oct; 6(10):e1001130. PubMed ID: 20949066
[TBL] [Abstract][Full Text] [Related]
11. Remission of Psoriasis in a Patient with Hepatocellular Carcinoma Treated with Sorafenib.
Antoniou EA; Koutsounas I; Damaskos C; Koutsounas S
In Vivo; 2016 09-10; 30(5):677-80. PubMed ID: 27566090
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib inhibits TPA-induced MMP-9 and VEGF expression via suppression of ERK/NF-κB pathway in hepatocellular carcinoma cells.
Chiang IT; Liu YC; Wang WH; Hsu FT; Chen HW; Lin WJ; Chang WY; Hwang JJ
In Vivo; 2012; 26(4):671-81. PubMed ID: 22773582
[TBL] [Abstract][Full Text] [Related]
13. Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion.
Schmitt M; Horbach A; Kubitz R; Frilling A; Häussinger D
J Hepatol; 2004 Aug; 41(2):274-83. PubMed ID: 15288477
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal Antibodies against Occludin Completely Prevented Hepatitis C Virus Infection in a Mouse Model.
Shimizu Y; Shirasago Y; Kondoh M; Suzuki T; Wakita T; Hanada K; Yagi K; Fukasawa M
J Virol; 2018 Apr; 92(8):. PubMed ID: 29437969
[TBL] [Abstract][Full Text] [Related]
15. Roles of epidermal growth factor receptor, claudin-1 and occludin in multi-step entry of hepatitis C virus into polarized hepatoma spheroids.
So CW; Sourisseau M; Sarwar S; Evans MJ; Randall G
PLoS Pathog; 2023 Dec; 19(12):e1011887. PubMed ID: 38157366
[TBL] [Abstract][Full Text] [Related]
16. Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection.
Liu S; Yang W; Shen L; Turner JR; Coyne CB; Wang T
J Virol; 2009 Feb; 83(4):2011-4. PubMed ID: 19052094
[TBL] [Abstract][Full Text] [Related]
17. Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes.
Kwon YC; Bose SK; Steele R; Meyer K; Di Bisceglie AM; Ray RB; Ray R
J Virol; 2015 Nov; 89(22):11549-56. PubMed ID: 26355082
[TBL] [Abstract][Full Text] [Related]
18. A New Signaling Pathway for HCV Inhibition by Estrogen: GPR30 Activation Leads to Cleavage of Occludin by MMP-9.
Ulitzky L; Lafer MM; KuKuruga MA; Silberstein E; Cehan N; Taylor DR
PLoS One; 2016; 11(1):e0145212. PubMed ID: 26731262
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma.
Sieghart W; Pinter M; Dauser B; Rohr-Udilova N; Piguet AC; Prager G; Hayden H; Dienes HP; Dufour JF; Peck-Radosavljevic M
J Hepatol; 2012 Sep; 57(3):592-9. PubMed ID: 22634341
[TBL] [Abstract][Full Text] [Related]
20. TNF superfamily members promote hepatitis C virus entry via an NF-κB and myosin light chain kinase dependent pathway.
Fletcher NF; Clark AR; Balfe P; McKeating JA
J Gen Virol; 2017 Mar; 98(3):405-412. PubMed ID: 27983476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
